Boston Scientific Corporation BSX
43.92
(0.76)
(1.70%)
as of 25 Sep
- Market cap
- $64.7B
- P/E
- 17.7×
Follow BSX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Boston Scientific Corporation (BSX) Net income
Boston Scientific Corporation's net income for fiscal 2025 was $2.9B, up 56.7% from $1.8B in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.7B. Over the past ten years it has ranged from −$239.0M (fiscal 2015) to $4.7B (fiscal 2019); the current reading is higher than 91% of that period. Net income has risen for 3 consecutive fiscal years. Boston Scientific Corporation ranks 4th of 149 Medical Devices companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | $2.9B | 56.66% |
| FY2024 | $1.8B | 15.95% |
| FY2023 | $1.6B | 128.08% |
| FY2022 | $698.0M | (32.95%) |
| FY2021 | $1.0B | — |
| FY2020 | −$82.0M | — |
| FY2019 | $4.7B | 181.27% |
| FY2018 | $1.7B | 1,506.73% |
| FY2017 | $104.0M | (70.03%) |
| FY2016 | $347.0M | — |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $904.0M | (32.49%) |
| Mar 2026 | $1.3B | 99.85% |
| Dec 2025 | $670.0M | (11.26%) |
| Sep 2025 | $755.0M | (5.03%) |
| 42 more quarters | Free account |
Against its own ten years
Low −$239.0M
High $4.7B
Ten-year median
$1.0B
Current reading's percentile
91
Net income against peers
| Company | Net income |
|---|---|
| ABT Abbott Laboratories compare | $5.4B |
| MDT Medtronic PLC compare | $5.3B |
| SYK Stryker Corporation compare | $3.7B |
| BSX Boston Scientific Corporation | $3.7B |
| GEHC GE HealthCare Technologies Inc. compare | $2.1B |
| PHG Koninklijke Philips N.V. compare | $1.3B |
| EW Edwards Lifesciences Corporation compare | $1.0B |
| DXCM DexCom, Inc. compare | $999.7M |
| STE STERIS plc compare | $808.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BSX
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement